Gemcitabine as Second-Line Treatment for Advanced Non–Small-Cell Lung Cancer: A Phase II Trial
Lucio Crinò, Anna Maria Mosconi, Giorgio V. Scagliotti et al. · Journal of Clinical Oncology · 1999
PURPOSE: To investigate the activity and toxicity of gemcitabine as a single agent in patients with advanced non-small-cell lung cancer (NSCLC) after recurrence or failure of previous treatment with a platinum-containing regimen. PATIENTS AND METHODS: From November 1995 to October 1997, 83 patients with stage IIIB or IV NSCLC received gemcitabine 1,000 mg/m(2) once a week for 3 weeks every 28 days. Responses were assessed every two treatment courses. The median age of the patients was 63 years; Eastern Cooperative Oncology Group performance status was 0 to 1 in 62 patients and 2 in 21 patients. The predominant histology was squamous (39 patients); 49 patients had stage IV disease and 34 patients had stage III disease (33 stage IIIB and one stage IIIA). RESULTS: Sixteen patients (19%) achieved a partial response to treatment; the median duration of response was 29 weeks (range, 6 to 50 weeks). Treatment was well tolerated: grade 2 to 3 (World Health Organization standardized response criteria) leukopenia and thrombocytopenia occurred in 23% and 20% of patients, respectively. Mild asthenia was observed in 16% of patients, and peripheral edema in 5% of patients. Nausea and vomiting were present in 16% of patients. CONCLUSION: In this experience, gemcitabine showed significant activity without relevant toxicity, mainly in patients who were previously responsive to chemotherapy. This suggests a possible role for gemcitabine as a second-line treatment in patients who had a previous response or achieved stable disease with a platinum-containing regimen.
Cited by 162 works. doi:10.1200/jco.1999.17.7.2081
Authors
- Lucio Crinò
- Anna Maria Mosconi
- Giorgio V. Scagliotti
- Giovanni Selvaggi
- Silvia Novello
- Marina Della Giulia
- Cesare Gridelli
- Antônio Rossi
- Cesare Calandri
- Filippo de Marinis
- M. A. Noseda
- Maurizio Tonato
References
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
- Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology.
- Polychemotherapy in advanced non small cell lung cancer: a meta-analysis
- Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.
- Management strategies for recurrent non-small cell lung cancer.
- New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.
- Synergistic interaction between cisplatin and gemcitabine in vitro.
- Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer.
- Gemcitabine: current status of phase I and II trials.
- Failure of vinorelbine to produce responses in pretreated non-small cell lung cancer patients.